Agile Therapeutics Received its Third Buy in a Row

By Carrie Williams

After H.C. Wainwright and Cantor Fitzgerald assigned a Buy rating to Agile Therapeutics in the last month, the company received another Buy, this time from Noble Financial. Analyst Caroline Palomeque reiterated a Buy rating on Agile Therapeutics (NASDAQ: AGRX) yesterday. The company’s shares closed yesterday at $2.52, close to its 52-week low of $1.82.

According to, Palomeque is ranked 0 out of 5 stars with an average return of -12.2% and a 38.1% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as ContraVir Pharmaceuticals Inc, Adamas Pharmaceuticals, and Corbus Pharmaceuticals.

Currently, the analyst consensus on Agile Therapeutics is Strong Buy and the average price target is $6.50, representing a 157.9% upside.

In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $8 price target.

Based on Agile Therapeutics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $0 and GAAP net loss of $7.1 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $7.8 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. engages in the development and commercialization of new prescription contraceptive products. Its product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company was founded on December 22, 1997 and is headquartered in Princeton, NJ.